William B.  Stilley, III net worth and biography

William Stilley, III Biography and Net Worth

William B. Stilley has served as our Chief Executive Officer since co-founding the company in December 2010. Prior to joining Adial Pharmaceuticals, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (NASDQ CLDA), where he worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the Company’s vasodilator drug for myocardial stress imaging. He has advised both public and private companies on financing and M&A transactions, and has been the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps.

 

Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He has guest lectured at the Darden School of Business in two courses on the management of life science companies, and serves on the Advisory Board of Virginia BIO, the statewide biotechnology organization, and previously served on Virginia BIO’s board of directors.

What is William B. Stilley, III's net worth?

The estimated net worth of William B. Stilley, III is at least $65,263.92 as of March 25th, 2020. Mr. Stilley, III owns 28,131 shares of Adial Pharmaceuticals stock worth more than $65,264 as of April 17th. This net worth evaluation does not reflect any other investments that Mr. Stilley, III may own. Learn More about William B. Stilley, III's net worth.

How do I contact William B. Stilley, III?

The corporate mailing address for Mr. Stilley, III and other Adial Pharmaceuticals executives is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. Adial Pharmaceuticals can also be reached via phone at (434) 422-9800 and via email at [email protected]. Learn More on William B. Stilley, III's contact information.

Has William B. Stilley, III been buying or selling shares of Adial Pharmaceuticals?

William B. Stilley, III has not been actively trading shares of Adial Pharmaceuticals in the last ninety days. Most recently, on Monday, November 29th, William B. Stilley III bought 400 shares of Adial Pharmaceuticals stock. The stock was acquired at an average cost of $64.75 per share, with a total value of $25,900.00. Learn More on William B. Stilley, III's trading history.

Who are Adial Pharmaceuticals' active insiders?

Adial Pharmaceuticals' insider roster includes Bankole Johnson (Insider), James Newman, Jr. (Director), and William Stilley, III (CEO). Learn More on Adial Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Adial Pharmaceuticals?

In the last twelve months, Adial Pharmaceuticals insiders bought shares 1 times. They purchased a total of 700 shares worth more than $1,918.00. The most recent insider tranaction occured on September, 29th when Director Kevin Schuyler bought 700 shares worth more than $1,918.00. Insiders at Adial Pharmaceuticals own 14.5% of the company. Learn More about insider trades at Adial Pharmaceuticals.

Information on this page was last updated on 9/29/2023.

William B. Stilley, III Insider Trading History at Adial Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2021Buy400$64.75$25,900.00View SEC Filing Icon  
3/25/2020Buy493$28.25$13,927.2528,131View SEC Filing Icon  
See Full Table

William B. Stilley, III Buying and Selling Activity at Adial Pharmaceuticals

This chart shows William B Stilley III's buying and selling at Adial Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adial Pharmaceuticals Company Overview

Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: $2.32
Low: $1.70
High: $2.46

50 Day Range

MA: $1.61
Low: $0.83
High: $3.26

2 Week Range

Now: $2.32
Low: $0.76
High: $14.00

Volume

1,209,517 shs

Average Volume

5,422,846 shs

Market Capitalization

$9.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48